← Leaderboards
Drew M. Pardoll
Johns Hopkins University
$27,059,898
Attributed
$35,568,553
Total exposure
28
Grants
16
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$35,568,553 · 28
By mechanism
R01$28,227,363 · 14
P30$3,891,719 · 4
P50$2,325,432 · 5
U19$999,990 · 3
R41$124,049 · 1
P01$0 · 1
Top collaborators
- Suzanne Louise Topalian15 shared
- Janis M. Taube11 shared
- Cynthia L Sears10 shared
- T.-C. Wu10 shared
- Lieping Chen5 shared
- Cornelia L Trimble5 shared
Most similar at Johns Hopkins University
Same institution · by research overlap
- Cornelia L Trimble$7,319,162
- Kellie Nicole Smith$2,071,828
- Richard Bruce Roden$11,133,737
- Janis M. Taube$2,419,751
- Sara Elizabeth Cosgrove$8,632,526
Others in their field
Top investigators on “Immune”
- Lawrence Corey · Fred Hutchinson Cancer Center$680,290,567
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$541,067,641
- Bambra Strokes · Ppd Development Lp$526,656,217
- Barton F Haynes · Duke University$470,748,611
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$342,310,423
- Judith S. Currier · University Of California Los Angeles$334,425,492
Research focus
ImmuneTumorT-LymphocyteCellsMalignant NeoplasmsResponseImmune ResponsePathway InteractionsBaseImmunotherapyNeoplastic CellCytokineCancer ImmunotherapyMediatingIn VivoProgramsImmune SystemSignal TransductionResearch PersonnelIn VitroMelanomaRegulationFundingImmunoregulation
Grant awards (141)
PD-1/PD-L1 modulation in cancer therapy$600,140
R01 · FY2025 · CA · contact PI
Cancer Immunology$299,086
P30 · FY2025 · CA · contact PI
PD-1/PD-L1 modulation in cancer therapy$570,133
R01 · FY2024 · CA · contact PI
Cancer Immunology$54,277
P30 · FY2024 · CA · contact PI
PD-1/PD-L1 modulation in cancer therapy$600,140
R01 · FY2023 · CA · contact PI
Role of YAP in Treg Function and YAP Targeting for Cancer Immunotherapy$367,087
R01 · FY2023 · CA · contact PI
Cancer Immunology$54,277
P30 · FY2023 · CA · contact PI
PD-1/PD-L1 modulation in cancer therapy$588,135
R01 · FY2022 · CA · contact PI
E3 ligase mediated control of Foxp3 expression and immune suppression-mechanisms and potential as immunotherapeutic target$379,055
R01 · FY2022 · AI · contact PI
Role of YAP in Treg Function and YAP Targeting for Cancer Immunotherapy$367,087
R01 · FY2022 · CA · contact PI
Cancer Immunology$54,277
P30 · FY2022 · CA · contact PI
PD-1/PD-L1 modulation in cancer therapy$600,139
R01 · FY2021 · CA · contact PI
E3 ligase mediated control of Foxp3 expression and immune suppression-mechanisms and potential as immunotherapeutic target$413,515
R01 · FY2021 · AI · contact PI
Role of YAP in Treg Function and YAP Targeting for Cancer Immunotherapy$374,578
R01 · FY2021 · CA · contact PI
Cancer Immunology Program - 03$36,924
P30 · FY2021 · CA · contact PI
PD-1/PD-L1 modulation in cancer therapy$672,206
R01 · FY2020 · CA · contact PI
E3 ligase mediated control of Foxp3 expression and immune suppression-mechanisms and potential as immunotherapeutic target$413,515
R01 · FY2020 · AI · contact PI
Role of YAP in Treg Function and YAP Targeting for Cancer Immunotherapy$369,912
R01 · FY2020 · CA · contact PI
Cancer Immunology Program - 03$36,924
P30 · FY2020 · CA · contact PI
PD-1/PD-L1 modulation in cancer therapy$473,681
R01 · FY2019 · CA · contact PI
E3 ligase mediated control of Foxp3 expression and immune suppression-mechanisms and potential as immunotherapeutic target$413,515
R01 · FY2019 · AI · contact PI
Role of YAP in Treg Function and YAP Targeting for Cancer Immunotherapy$363,204
R01 · FY2019 · CA · contact PI
Multi-institutional analysis of multiplex immunofluorescence panels in tumor tissue specimens$293,932
R01 · FY2019 · CA · contact PI
Cancer Immunology Program - 03$36,924
P30 · FY2019 · CA · contact PI
PD-1/PD-L1 modulation in cancer therapy$488,332
R01 · FY2018 · CA · contact PI
Cancer Immunology Program - 03$36,915
P30 · FY2018 · CA · contact PI
Cancer Immunology Program - 03$6,864
P30 · FY2018 · CA · contact PI
Cancer Immunology Program - 03$2,068
P30 · FY2018 · CA · contact PI
PD-1/PD-L1 modulation in cancer therapy$488,332
R01 · FY2017 · CA · contact PI
Cancer Immunology Program - 03$36,868
P30 · FY2017 · CA · contact PI
PD-1/PD-L1 modulation in cancer therapy$488,332
R01 · FY2016 · CA · contact PI
Role of Tc17 cells in tumor immunotherapy$336,150
R01 · FY2016 · CA · contact PI
Enterotoxigenic Bacteroides fragilis: A bacterial promoter of colon oncogenesis$548,647
R01 · FY2014 · CA
B7-H1/PD-1 modulation in cancer therapy$443,937
R01 · FY2014 · CA · contact PI
The Role of EOS in Regulatory T-cell Biology.$405,900
R01 · FY2014 · AI · contact PI
Mechanisms of TH17 Inflammation-Induced Colon Carcihogenesis$320,189
R01 · FY2014 · CA
Enterotoxigenic Bacteroides fragilis: A bacterial promoter of colon oncogenesis$487,000
R01 · FY2013 · CA
B7-H1/PD-1 modulation in cancer therapy$437,199
R01 · FY2013 · CA · contact PI
The Role of EOS in Regulatory T-cell Biology.$381,546
R01 · FY2013 · AI · contact PI
Mechanisms of TH17 Inflammation-Induced Colon Carcihogenesis$310,286
R01 · FY2013 · CA
A phase I trial to assess the immunogenicity, safety, tolerability and efficacy o$193,870
P50 · FY2013 · CA
Developmental Research Program$90,831
P50 · FY2013 · CA · contact PI
Enterotoxigenic Bacteroides fragilis: A bacterial promoter of colon oncogenesis$570,309
R01 · FY2012 · CA
B7-H1/PD-1 modulation in cancer therapy$471,842
R01 · FY2012 · CA · contact PI
The Role of EOS in Regulatory T-cell Biology.$405,900
R01 · FY2012 · AI · contact PI
Mechanisms of TH17 Inflammation-Induced Colon Carcihogenesis$330,091
R01 · FY2012 · CA
A phase I trial to assess the immunogenicity, safety, tolerability and efficacy o$210,399
P50 · FY2012 · CA
Developmental Research Program$99,556
P50 · FY2012 · CA · contact PI
Enterotoxigenic Bacteroides fragilis: A bacterial promoter of colon oncogenesis$521,517
R01 · FY2011 · CA
B7-H1/PD-1 modulation in cancer therapy$479,334
R01 · FY2011 · CA · contact PI
The Role of EOS in Regulatory T-cell Biology.$405,900
R01 · FY2011 · AI · contact PI
Mechanisms of TH17 Inflammation-Induced Colon Carcihogenesis$330,091
R01 · FY2011 · CA
A phase I trial to assess the immunogenicity, safety, tolerability and efficacy o$208,423
P50 · FY2011 · CA
Developmental Research Program$100,715
P50 · FY2011 · CA · contact PI
Enterotoxigenic Bacteroides fragilis: A bacterial promoter of colon oncogenesis$534,116
R01 · FY2010 · CA
B7-H1/PD-1 modulation in cancer therapy$510,450
R01 · FY2010 · CA · contact PI
The Role of EOS in Regulatory T-cell Biology.$410,000
R01 · FY2010 · AI · contact PI
Identification of Novel Immune Cell- the NKDC$386,641
R01 · FY2010 · AI · contact PI
Mechanisms of TH17 Inflammation-Induced Colon Carcihogenesis$340,300
R01 · FY2010 · CA
Analysis of the STAT3 Pathway In Tumor Tolerance and Immune Evasion$282,659
R01 · FY2010 · CA · contact PI
A phase I trial to assess the immunogenicity, safety, tolerability and efficacy o$210,262
P50 · FY2010 · CA
COMMON EQUIPMENT$112,504
P30 · FY2010 · CA · contact PI
GLASSWARE WASHING$107,817
P30 · FY2010 · CA · contact PI
Developmental Research Program$102,700
P50 · FY2010 · CA · contact PI
Identification of Novel Immune Cell- the NKDC$390,546
R01 · FY2009 · AI · contact PI
Analysis of the STAT3 Pathway In Tumor Tolerance and Immune Evasion$282,659
R01 · FY2009 · CA · contact PI
EVALUATE LAG3 AND OTHER IMMUNE MODULATORS$230,904
U19 · FY2009 · CA · contact PI
A phase I trial to assess the immunogenicity, safety, tolerability and efficacy o$212,970
P50 · FY2009 · CA
COMMON EQUIPMENT$114,051
P30 · FY2009 · CA · contact PI
GLASSWARE WASHING$109,300
P30 · FY2009 · CA · contact PI
Developmental Research Program$106,022
P50 · FY2009 · CA · contact PI
COMMON EQUIPMENT$44,966
P30 · FY2009 · CA · contact PI
GLASSWARE WASHING$43,093
P30 · FY2009 · CA · contact PI
Identification of Novel Immune Cell- the NKDC$390,546
R01 · FY2008 · AI · contact PI
Analysis of Lag-3 in Regulatory T cell Function$321,523
R01 · FY2008 · AI · contact PI
Analysis of the STAT3 Pathway In Tumor Tolerance and Immune Evasion$282,659
R01 · FY2008 · CA · contact PI
EVALUATE LAG3 AND OTHER IMMUNE MODULATORS$232,011
U19 · FY2008 · CA · contact PI
COMMON EQUIPMENT$54,972
P30 · FY2008 · CA · contact PI
GLASSWARE WASHING$52,682
P30 · FY2008 · CA · contact PI
Identification of Novel Immune Cell- the NKDC$397,503
R01 · FY2007 · AI · contact PI
Antigen Specific Immunotherapy with Transduced HSC$344,936
R01 · FY2007 · CA · contact PI
Analysis of Lag-3 in Regulatory T cell Function$327,750
R01 · FY2007 · AI · contact PI
Analysis of the STAT3 Pathway In Tumor Tolerance and Immune Evasion$282,659
R01 · FY2007 · CA · contact PI
EVALUATE LAG3 AND OTHER IMMUNE MODULATORS$237,577
U19 · FY2007 · CA · contact PI
COMMON EQUIPMENT$54,972
P30 · FY2007 · CA · contact PI
GLASSWARE WASHING$52,682
P30 · FY2007 · CA · contact PI
Identification of Novel Immune Cell- the NKDC$408,125
R01 · FY2006 · AI · contact PI
Antigen Specific Immunotherapy with Transduced HSC$355,238
R01 · FY2006 · CA · contact PI
Analysis of Lag-3 in Regulatory T cell Function$337,539
R01 · FY2006 · AI · contact PI
Analysis of New Dendritic Cell Costimulatory Molecule$319,316
R01 · FY2006 · AI · contact PI
Analysis of the STAT3 Pathway In Tumor Tolerance and Immune Evasion$290,360
R01 · FY2006 · CA · contact PI
EVALUATE LAG3 AND OTHER IMMUNE MODULATORS$149,698
U19 · FY2006 · CA · contact PI
COMMON EQUIPMENT$54,972
P30 · FY2006 · CA · contact PI
GLASSWARE WASHING$52,682
P30 · FY2006 · CA · contact PI
Antigen Specific Immunotherapy with Transduced HSC$363,788
R01 · FY2005 · CA
Analysis of Lag-3 in Regulatory T cell Function$345,662
R01 · FY2005 · AI
Analysis of New Dendritic Cell Costimulatory Molecule$327,000
R01 · FY2005 · AI
EVALUATE LAG3 AND OTHER IMMUNE MODULATORS$149,800
U19 · FY2005 · CA
Antigen Specific Immunotherapy with Transduced HSC$363,788
R01 · FY2004 · CA
Analysis of Lag-3 in Regulatory T cell Function$361,537
R01 · FY2004 · AI
Analysis of New Dendritic Cell Costimulatory Molecule$327,000
R01 · FY2004 · AI
Antigen Specific Immunotherapy with Transduced HSC$363,788
R01 · FY2003 · CA
Analysis of New Dendritic Cell Costimulatory Molecule$327,000
R01 · FY2003 · AI
SIGE7/ASP70 DNA VACCINE IN PTS WITH HPV LESIONS &HIV$0
P50 · FY2003 · CA
Analysis of New Dendritic Cell Costimulatory Molecule$327,000
R01 · FY2002 · AI
ANALYSIS OF E7 SPECIFIC T CELLS USING MHC-1GG MOLECULES$327,000
R01 · FY2002 · AI
Core--Common Equipment Facility$250,404
P30 · FY2002 · CA
Core--Common Equipment Facility$250,404
P30 · FY2002 · CA
Core--Glassware Washing Facility$250,404
P30 · FY2002 · CA
Core--Glassware Washing Facility$250,404
P30 · FY2002 · CA
TRANSGENIC MODELS FOR PROSTATE CANCER AND AUTOIMMUNITY$131,614
P50 · FY2002 · CA
TRANSGENIC MODELS FOR PROSTATE CANCER AND AUTOIMMUNITY$131,614
P50 · FY2002 · CA
Core--Laboratory$0
P50 · FY2002 · AT
Analysis of E7 specific T cells using MHC-IgG molecules$0
P01 · FY2002 · AI
AMPLIFICATION OF VACCINE RESPONSE--T CELL ACTIVATION$0
U19 · FY2002 · CA
PARACRINE CYTOKINE DELIVERY FOR BRAIN TUMOR IMMUNOTHERAPY$0
U19 · FY2002 · CA
ANALYSIS OF E7 SPECIFIC T CELLS USING MHC-1GG MOLECULES$327,333
R01 · FY2001 · AI
Core--Glassware Washing Facility$250,404
P30 · FY2001 · CA
Core--Glassware Washing Facility$250,404
P30 · FY2001 · CA
Core--Common Equipment Facility$250,404
P30 · FY2001 · CA
Core--Common Equipment Facility$250,404
P30 · FY2001 · CA
RENAL CANCER ANTIGENS RECOGNIZED BY CD4 T CELLS$218,796
R01 · FY2001 · CA
Core--Common Equipment Facility$189,195
P30 · FY2001 · CA
Core--Glassware Washing Facility$189,195
P30 · FY2001 · CA
TRANSGENIC MODELS FOR PROSTATE CANCER AND AUTOIMMUNITY$131,614
P50 · FY2001 · CA
TRANSGENIC MODELS FOR PROSTATE CANCER AND AUTOIMMUNITY$131,614
P50 · FY2001 · CA
PARACRINE CYTOKINE DELIVERY FOR BRAIN TUMOR IMMUNOTHERAPY$0
U19 · FY2001 · CA
Core--Laboratory$0
P50 · FY2001 · AT
AMPLIFICATION OF VACCINE RESPONSE--T CELL ACTIVATION$0
U19 · FY2001 · CA
Analysis of E7 specific T cells using MHC-IgG molecules$0
P01 · FY2001 · AI
ANALYSIS OF E7 SPECIFIC T CELLS USING MHC-1GG MOLECULES$328,000
R01 · FY2000 · AI
RENAL CANCER ANTIGENS RECOGNIZED BY CD4 T CELLS$213,338
R01 · FY2000 · CA
TRANSGENIC MODELS FOR PROSTATE CANCER AND AUTOIMMUNITY$131,614
P50 · FY2000 · CA
TRANSGENIC MODELS FOR PROSTATE CANCER AND AUTOIMMUNITY$131,614
P50 · FY2000 · CA
HPV 16 MOUSE CANCER MODEL TO TEST HSP70-BASED VACCINES$124,049
R41 · FY2000 · CA
Core--Laboratory$0
P50 · FY2000 · AT
AMPLIFICATION OF VACCINE RESPONSE--T CELL ACTIVATION$0
U19 · FY2000 · CA
PARACRINE CYTOKINE DELIVERY FOR BRAIN TUMOR IMMUNOTHERAPY$0
U19 · FY2000 · CA
PARACRINE CYTOKINE DELIVERY FOR BRAIN TUMOR IMMUNOTHERAPY$0
U19 · FY2000 · CA
PARACRINE CYTOKINE DELIVERY FOR BRAIN TUMOR IMMUNOTHERAPY$0
U19 · FY2000 · CA
Analysis of E7 specific T cells using MHC-IgG molecules$0
P01 · FY2000 · AI